Relenza zanamivir GG167 neuraminidase inhibitor: Phase III data; awaiting approval in Australia

By WIR Staff | Aug 31, 1998 | 7:00 AM GMT

Results of Phase III testing conducted in Australia by partner Glaxo Wellcome showed that

Read the full 146 word article

How to gain access

Continue reading with a
two-week free trial.